Cardiometabolic Diseases Research
Our research and development has resulted in important achievements in recent years, especially in thromboembolic diseases and type 2 diabetes. Our current research efforts focus on new strategies for the treatment of diabetes, obesity, non-alcoholic Steatohepatitis (NASH), diabetic retinopathy, and chronic kidney disease. Together these therapies complement each other to reduce the risk of cardiovascular mortality and morbidity. Around 300 scientists work in our fully integrated drug discovery centre of excellence for Cardiometabolic research at sites in Biberach, Germany and Ridgefield, CT, USA.
Our Discovery Research focus is on:
- Type 2 diabetes
- Micro- and macrovascular complications of diabetes – e.g. diabetic retinopathy, diabetic nephropathy, chronic kidney diseases, CV outcomes
- Liver diseases – e.g. NASH
- Obesity
-
-
Diabetes
Listen as Dr Stephen Hull explains the link between type 2 diabetes and heart disease and provides practical advice for people living with these conditions
-
Diabetes
Learn about the relationship between type 2 diabetes and cardiovascular disease
-
-
-
Diabetes
Type 2 Diabetes is a serious pandemic… with serious complications
-
Research & Development
Our new discovery research strategy aims at enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need.
-
Diabetes Awareness
Diabetes
Diabetes is a common medical condition affecting 415 million people today; and that number is on the rise.
-
diabetes-youtube-channel
-
Type 2 Diabetes and the Kidneys
-
Introduction to SGLT2 inhibition